DNA molecule illustration

Image source: Shutterstock/Sergey Nivens

Lesion segregation

Explaining the extreme complexity of mutations in tumor genomes

Scientists from the German Cancer Research Center (DKFZ) and the Universities of Cambridge and Edinburgh have been studying the evolution of tumors following chemical damage. They discovered that the DNA lesions caused by the chemical are not eliminated immediately, but are passed on unrepaired over several rounds of cell division.

This "lesion segregation" can drive unexpectedly complex patterns of mutations in the tumor genome, as the scientists have now published in the journal Nature.

Tobacco smoke, many chemicals or the UV radiation of sunlight: Numerous environmental and lifestyle factors damage the genetic material of our cells and can thus trigger cancer. These factors modify individual DNA building blocks, called nucleotides, in such a way that they are no longer correctly recognized when the DNA is duplicated. The consequence: False "counterparts" are incorporated into the newly synthesized DNA strand. Cells have a variety of repair systems that can remove and replace such defective nucleotides. But which defects are repaired and which escape repair and can lead to cancer-promoting mutations? What effect does this have on the mutation pattern of tumor cells? And how do these mutations spread during the clonal expansion of individual cells during tumorigenesis?

Recommended article

Photo

Susceptibility to future drugs

Exploiting the carelessness of cancer cells

Could the ability of cancer cells to quickly alter their genome be used as a weapon against malignant tumours? Researchers at Uppsala University have succeeded in developing a substance that has demonstrated promising results in experiments on both animal models and human cancer cells. The study is published in the journal Nature Communications.

Answering these questions was the goal of a collaboration among the laboratories of Duncan Odom at the DKFZ and the University of Cambridge's Cancer Research UK – Cambridge Institute, Martin Taylor and Colin Semple at the University of Edinburgh's MRC Human Genetics Unit, as well as Paul Flicek at EMBL EBI and Professor Nuria Lopez-Bigas at IRB Barcelona. These researchers used the DNA-damaging chemical diethylnitrosamine to induce hundreds of liver tumors in mice and analyzed the genomes of these cancers. On average, this chemical mutagen caused about 60,000 point mutations in the genome of each cancer cell.

To their surprise, the scientists discovered during the analysis of the mutation signatures that the lesions caused by the chemical remains largely unrepaired over several cell generations. The two DNA strands, which were damaged independently of each other, are separated during cell division. The two resulting daughter cells then develop two different mutation profiles. The researchers refer to this as "lesion segregation".

Persistent DNA lesions induced by chemotherapeutic agents also segregate and produce several generations of further mutations. We need to be aware of this therapeutically, and in future drug development

Martin Taylor

During further replication rounds, the lesions repeatedly lead to new, different mutations, since four different DNA nucleotides can be incorporated at the defective site. Cancer cells are usually exposed to several mutagenic events, so that this cycle of DNA damage and lesion segregation repeats over time, ultimately resulting in extremely complex patterns of mutations in cancers. The mutations affect important genes known as cancer drivers. In their study, the scientists found defects in genes of the cancer-promoting BRAF, RAS and RAF signaling pathways. "In the end, those cancer cells that carry the most favorable pattern of mutations will prevail. They can grow the fastest, escape the immune system and possibly survive therapies better," says lead author Sarah Aitken, a Cambridge-based clinician-scientist. 

"Persistent DNA lesions induced by chemotherapeutic agents also segregate and produce several generations of further mutations. We need to be aware of this therapeutically, and in future drug development," said Martin Taylor from University of Edinburgh's MRC Human Genetics Unit. "Thanks to the concept of lesion segregation, we now understand better how the surprising complexity of mutations in cancer cells can arise," summarizes Duncan Odom. "This may help explain how cancer cells can react so flexibly to survival challenges, which in turn helps them to quickly develop resistance to drugs or adapt to foreign tissue environments."


Source: German Cancer Research Center (DKFZ)

25.06.2020

Read all latest stories

Related articles

Photo

Cause for lack of immune defense against tumors discovered

Improving immunotherapy for cancer

Our immune system not only protects us against infection, but also against cancer. This powerful protection is based in particular on the activation of special cells of the immune system, CD8+ T…

Photo

Medulloblastoma

New insights into deadly brain tumours in children

The causes of 40 percent of all cases of certain medulloblastoma – dangerous brain tumors affecting children – are hereditary. These are the findings of a recent genetic analysis carried out by…

Photo

Gastric squamous-columnar junction cancer

The role of stem cells in deadly gastric SCJ cancer

A study led by scientists from Cornell University provides important new insights into a common and deadly type of gastric cancer. Incidence of this cancer, called gastric squamous-columnar junction…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
BD/QIAGEN PAXgene Blood ccfDNA Tube

Liquid Biopsy

BD/QIAGEN PAXgene Blood ccfDNA Tube

BD – Becton Dickinson
Eppendorf – BioSpectrometer fluroescence

Research Use Only (RUO)

Eppendorf – BioSpectrometer fluroescence

Eppendorf AG